Comparative Pharmacology
Head-to-head clinical analysis: CAPTOPRIL AND HYDROCHLOROTHIAZIDE versus DIUCARDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPTOPRIL AND HYDROCHLOROTHIAZIDE versus DIUCARDIN.
CAPTOPRIL AND HYDROCHLOROTHIAZIDE vs DIUCARDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, resulting in vasodilation and decreased aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
1 tablet (captopril 25 mg / hydrochlorothiazide 15 mg) orally once daily, titrated up to a maximum of 1 tablet (captopril 50 mg / hydrochlorothiazide 25 mg) twice daily.
Hydrochlorothiazide 25-50 mg orally once daily, titrated based on response. Maximum dose 100 mg/day.
None Documented
None Documented
Captopril: ~2 hours (prolonged to 6-8 hours in heart failure or renal impairment). Hydrochlorothiazide: 5.6-14.8 hours (mean ~9.6 hours; prolonged in renal impairment).
Terminal elimination half-life is approximately 18-24 hours in normal renal function. This prolongs significantly in renal impairment, requiring dose adjustment.
Captopril: renal (95%), primarily as unchanged drug and disulfide metabolites. Hydrochlorothiazide: renal (≥95%) as unchanged drug via tubular secretion.
Primarily renal excretion: approximately 60-70% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination accounts for about 20-30%, with some enterohepatic circulation.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic